Life Science Intelligence

  This market snapshot from Life Science Intelligence provides an analysis of the global market for wearable monitoring devices. These devices are intended to continuously collect and track vital signs for patient or personal monitoring. Devices covered within the scope of this analysis include wearable devices for physiological monitoring of heart rate, electrocardiogram (ECG), oxygen saturation, blood pressure, sleep apnea, exercise/exertion, respiration, body temperature, and other vital signs. To read more about visit here: https://www.lifesciencemarketresearch.com/market-reports/wearable-monitoring-devices-2024

In late February 2025, Biotronik made headlines with a bold strategic move that redefines its role in the implantable cardiac rhythm management (CRM) device market.  On February 27th , the company announced that it would be divesting its vascular intervention business to focus more intently on its portfolio of implantable solutions. This shift is part of a broader strategy to better serve an aging population with increasing cardiac care needs and to position Biotronik at the forefront of the evolving implantable  cardiac rhythm management device market . Let’s explore the numbers driving this shift, the challenges and opportunities facing Biotronik, and how this new direction positions the company for future growth. Biotronik’s Strategy Biotronik’s pivot toward implantable CRM devices, alongside its expansion into the  neuromodulation market  with products like the Prospera Spinal Cord Stimulation (SCS) system, highlights the company’s vision for sustained growth in ...

Under the direction of President and CEO Peter Fischer, InkSpace Imaging is pioneering a breakthrough in MRI technology with ultralight, flexible, body-conforming MRI coils. The company was initially focused on pediatrics, addressing a long-standing gap in MRI accessibility and patient comfort for children, who often require sedation due to poorly fitting, rigid coils. Building on this foundation, InkSpace Imaging has expanded its product line, securing FDA clearance for adult MRI applications as well, bringing the same advancements in comfort and imaging quality to a broader patient population. By replacing uncomfortable, one-size-fits-all coils with customized, high-performance solutions, InkSpace Imaging is improving image quality, reducing scan times, and enhancing patient comfort — all while making MRI more efficient for hospitals and healthcare providers. Its coils are plug-and-play compatible with Siemens, GE, and Philips MRI systems, requiring no workflow or software modificati...

In a significant move within the medtech sector, Boston Scientific has re-entered the renal denervation (RDN) race with a bold acquisition. On March 5th, 2025, the company announced the $540 million acquisition of SoniVie Ltd., an Israeli firm developing an ultrasound-based renal denervation system to treat uncontrolled hypertension. This acquisition signals Boston Scientific’s confidence in the future of the renal denervation devices market , a field that’s showing strong momentum following recent FDA approvals from Medtronic and Recor Medical. This article will delve into Boston Scientific’s renal denervation strategy, the potential of the RDN market, and how this acquisition could reshape the hypertension treatment landscape in the years to come. Two Different Approaches: Boston Scientific’s Renal Denervation Strategy Boston Scientific’s renal denervation strategy sets it apart from its competitors, as the company focuses on ultrasound technology in a field where most others, like ...

Origin Story Nanochon was founded by Benjamin Holmes and Nathan Castro, two biomedical engineers with a shared passion for tissue regeneration. Their work at George Washington University led them to a breakthrough in biomaterials, inspiring them to create a scalable, synthetic alternative to cartilage grafting. “For me, the idea of bringing my research into the real world was a lightbulb moment,” Holmes said. “I didn’t want my work to be just another academic paper — I wanted to develop something that could actually help patients return to a pain-free, active lifestyle.” His motivation became even more personal as he engaged with orthopedic surgeons and sports medicine specialists who agreed that one of the biggest unmet needs in orthopedics is treating patients between cartilage injury and knee replacement. “Many are too young, or their cartilage damage is not yet severe enough for total knee arthroplasty, but they’re in pain and need a real solution — not just a temporary fix,” Holme...

The medtech industry witnessed another significant shift in February 2025 as Teleflex made two major announcements that have the potential to reshape its future. On February 27th, Teleflex revealed plans to divide into two separate publicly traded entities, each focusing on different aspects of the business. In addition, the company announced that it would acquire BIOTRONIK’s vascular intervention business for approximately $791 million. This strategic move underscores Teleflex’s commitment to expanding its footprint in the vascular market. As Teleflex transitions into this new phase, the focus shifts to understanding what this acquisition means for the company’s growth and the broader  spinal cord stimulation market . The decision to integrate BIOTRONIK’s vascular intervention portfolio further strengthens Teleflex’s presence in the vascular access and interventional fields. But what does this deal signal about the company’s future and the landscape of the vascular market? In this...

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive FDA 510(k) clearance, enter new strategic partnerships, appoint new executives, and much more on the road to  LSI USA  ’25 in Dana Point, CA (March 17–21). Arcuro Medical Received FDA 510(k) clearance for its SuperBall RC system for rotator cuff indications. The SuperBall RC system is based on the company’s SuperBall technology utilized in meniscus repairs and is designed to enable safe, easy fixation of rotator cuff augmentation grafts. Berg Capital Partners Announced a strategic partnership with Vesica Health, developer of AssureMDx, to enhance bladder cancer diagnostics. Vesica’s AssureMDx utilizes a simple urine sample to assess the presence of specific DNA biomarkers associated with bladder cancer. Brainomix Partnered with Medtronic Neurovascular to enhance stroke care across Western Europe via Brainomix’s AI-driven imaging technology and Medtronic’s expertise ...